← 返回

CD8(+) T 细胞中 TCR 诱导的 FOXP3 表达损害了它们的抗肿瘤活性

英文原题:TCR-induced FOXP3 expression by CD8(+) T cells impairs their anti-tumor activity.

查看英文原题

TCR-induced FOXP3 expression by CD8(+) T cells impairs their anti-tumor activity.

PubMed 2021/12/29(内容时间) Cancer Lett Q1 · IF 11.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

使用CD8 + T淋巴细胞的过继细胞转移疗法在根除转移性恶性肿瘤方面显示出有希望的结果。然而,若干调控机制限制了其疗效。

我们研究了转录因子FOXP3的表达对CD8 + T细胞功能和抗肿瘤免疫的作用。在此我们显示,CD8 + T细胞的次优T细胞受体刺激在体外上调FOXP3。类似地,转移到荷瘤小鼠体内的CD8 T细胞在体内上调FOXP3。CD8 + T细胞中FOXP3的细胞内在缺失导致TCR刺激后功能改善以及体内更好的抗肿瘤反应。抑制FOXP3/NFAT相互作用同样改善了CD8 + T细胞功能。TCR刺激后细胞的转录组分析显示,与FOXP3-wt CD8 + T细胞相比,FOXP3缺陷型CD8 + T细胞中参与对IFN-γ、IFN-α反应、炎症反应、IL-6/JAK/STAT、G2M检查点和IL-2/STAT信号传导的基因富集。

我们的结果提示,肿瘤微环境中CD8 + T细胞对FOXP3的短暂表达限制了其抗肿瘤活性,这对改善免疫治疗期间的T细胞反应具有明确意义。

展开英文摘要原文

Adoptive cell transfer therapy using CD8 + T lymphocytes showed promising results eradicating metastatic malignancies.

However, several regulatory mechanisms limit its efficacy. We studied the role of the expression of the transcription factor FOXP3 on CD8 + T cell function and anti-tumor immunity.

Here we show that suboptimal T cell receptor stimulation of CD8 + T cells upregulates FOXP3 in vitro. Similarly, CD8 T cells transferred into tumor-bearing mice upregulate FOXP3 in vivo. Cell-intrinsic loss of FOXP3 by CD8 + T cells resulted in improved functionality after TCR stimulation and better antitumor responses in vivo.

Inhibition of the FOXP3/NFAT interaction likewise improved CD8 + T cell functionality. Transcriptomic analysis of cells after TCR stimulation revealed an enrichment of genes implicated in the response to IFN-γ, IFN-α, inflammatory response, IL-6/JAK/STAT, G2M checkpoint and IL-2/STAT signaling in FOXP3-deficient CD8 + T cells with respect to FOXP3-wt CD8 + T cells.

Our results suggest that transient expression of FOXP3 by CD8 + T cells in the tumor microenvironment restrains their anti-tumor activity, with clear implications for improving T cell responses during immunotherapy.

论文信息

作者
Lozano T、Conde E、Martín-Otal C、Navarro F、Lasarte-Cia A、Nasrallah R、Alignani D、Gorraiz M
第一作者单位
Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain. Electronic address: tlmoreda@unav.es.Spain
通讯作者单位
Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain. Electronic address: jjlasarte@unav.es.Spain
文献类型
非美国政府资助研究
期刊
Cancer letters2022 Mar 1
原文标识
PubMed 34973390 · DOI 10.1016/j.canlet.2021.12.030